Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
PlexusDx Precision Peptide Genetic Testing ($298) analyzes variants in GIPR and FTO, and MC4R genes to identify how your body responds to GLP-1 therapythis helps your provider choose semaglutide, tirzepatide, or dual therapy best suited to your genetic peptide pathways
March 20, 2024
Honestly answered, off-label noted
In addition to cardiovascular outcomes, GLP-1 RAs have been studied in various fields, including endocrine disorders, renal diseases, and neurological conditions, generating encouraging findings in these areas
Increased resting heart rate has been observed in clinical trials, with average increases of 2-4 beats per minute according to the FDA prescribing information
Impact of Increased Residual Gastric Content on Clinical Consequences By increasing the risk of RGC, the use of GLP-1 RAs can have negative clinical consequences on patient outcomes
